Canine IBD Hero Mb 2x

The Canine
CE-IBD Assay

Introducing the first diagnostic of its kind

Canine IBD Feature 01 Dskt

Let’s help make your patients healthier faster

DIAGNOSING CE/IBD IS DIFFICULT, INVASIVE, EXPENSIVE

It can take significant time to determine if a dog is suffering from Chronic Enteropathy (CE)/Inflammatory Bowel Disease (IBD). Current approaches can become increasingly invasive for pets while adding to the cost and concern for pet owners.

NOW, THERE’S A BREAKTHROUGH

Antech Diagnostics is accelerating the diagnosis of CE/IBD with the Canine CE-IBD Assay. For the first time, a blood test can assess three gastrointestinal biomarkers and help determine the presence of CE/IBD in dogs with a high level of accuracy.

What is CE/IBD?

It is a persistent and complex disease caused by a specific reaction to chronic irritation of the intestinal tract. This results in inflammation that interferes with a dog’s ability to digest and absorb nutrients, causing a variety of symptoms, including vomiting and/or chronic diarrhea. Dogs with CE/IBD may experience weight loss and poor appetite. Over time, this can result in poor body condition, muscle loss, a poor coat, and negatively impact the dog’s overall health and quality of life.

Sign up to Learn More
Key Features and Benefits
01
Uses trusted and understood technology (ELISA)
02
Quick turnaround times
03
Noninvasive
04
Affordable for pet owner
05
Accelerates diagnostic workup
06
Triple utility: diagnosis, treatment and monitoring
07
Provides deeper clinical insights via biomarkers
08
Helps improve compliance with therapeutic recommendations and dietary modifications
09
Preserves the bond between practitioner and pet owner

What the Canine CE-IBD Assay is telling you

By using well-known and trusted ELISA technology to assess three key biomarkers—bacterial proliferation, intestinal inflammation, and gliadin sensitivity—the Canine CE-IBD Assay can deliver one of two results: Consistent with CE/IBD or Not Consistent with CE/IBD.

From there, you can tailor your diagnostic and treatment plan based on the biomarkers.

Antech Canine IBD Infographic Decision Tree 02 071620
A Closer Look at the Biomarkers

Bacterial Proliferation

Anti-OmpC Porins Surface Antigens IgA antibodies: Single best marker to differentiate IBD in canine patients

  • Increases in Escherichia-like microorganism frequently observed in the small intestinal microflora of dogs with IBD
  • Selected E. coli clone (isolated from small intestines of CE/IBD cohort dogs)
  • Detection of IgA antibody against the outer membrane porin C (OmpC) of E. coli

Intestinal Inflammation

Anti-Canine Calprotectin IgA antibodies

  • Histological evidence of gut inflammation in dogs with CE/IBD and other inflammatory conditions
  • Well-established association between calprotectin and gut inflammation
  • Antibodies against calprotectin fusion genes cloned from dogs

Gliadin (Gluten) Sensitivity

Anti-Gliadin IgA antibodies

  • Titrates antibodies against gliadins (non-celiac gliadin sensitivity, NCGS)
  • Antibodies against core immunogenic peptides from gliadins
  • Predominant peptides after digestion by gastric fluids from CE/IBD

Any time is a good time to use Canine CE-IBD Assay

This tool can be helpful at any point in the diagnostic workup, from serving as an early indicator to evaluating a pet's progress. A thorough workup of the gastrointestinal (GI) signs is still recommended, including ruling out parasites, investigating the presence of a GI foreign body, identifying neoplasia with diagnostic imaging, and additional testing that could include endoscopy and biopsies.

Initial
Symptoms

The ideal first diagnostic usage occurs when a dog has been experiencing symptoms for about 3–7 days.

Persistent
Symptoms

A second opportunity occurs when symptoms have persisted for 14–30 days or the dog has not responded to initial treatment approaches.

Therapeutic
Monitoring

The Canine CE-IBD Assay also works for monitoring response to dietary changes and treatment every 2–4 weeks initially and can be repeated as needed within 4–8 weeks.
Canine IBD Feature 02 Mb 2x

Provide Relief Sooner

With a quick turnaround time and a high level of accuracy as to whether or not symptoms are consistent with CE/IBD, the Canine CE-IBD Assay accelerates the diagnostic process and helps uncover possible causes and provides treatment guidance.

This is great news...

For patients,

because it’s a non-invasive test that helps you direct further diagnostic testing such as imaging or endoscopy, design an effective treatment plan, and monitor response.

For clients,

because it builds confidence in your recommendations for additional testing and supports your treatment plan.

For your staff,

because the results will help monitor a patient's response to treatment and the pet owner's compliance with dietary changes.

For veterinarians,

because it saves time and steps, strengthens the trust between you and your clients, and assists you in doing what everyone wants...providing evidence-based advice to pet owners and helping dogs enjoy a better quality of life.

Sign up to learn more about the Canine CE-IBD Assay

RenalTech™

Take the surprise out of chronic kidney disease with artificial intelligence

Available exclusively through Antech, RenalTech™ is a breakthrough in predictive medicine. Powered by artificial intelligence, RenalTech™ uses common serum and urine diagnostics to predict whether a cat will develop chronic kidney disease in the next two years—with greater than 95% accuracy.

Learn More
CADET® BRAF and CADET® BRAF-PLUS

Achieve accurate and early diagnosis of TCC/UC

CADET® BRAF evaluates urine samples from dogs for the presence of cells containing a mutation for canine bladder/prostate cancer (TCC/UC). It’s cutting-edge technology that is accurate, affordable, and convenient for both veterinarian and pet owner.

Learn More
Ibd announcement 190x190

Innovations
Close
The Canine CE-IBD Assay
Antech accelerates the diagnosis of IBD with a simple blood test
Learn More